收稿日期: 2022-03-19
网络出版日期: 2022-08-11
基金资助
国家自然科学基金(81872086);北京大学人民医院研究与发展基金(RDY2018-18)
Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma
Received date: 2022-03-19
Online published: 2022-08-11
Supported by
the National Natural Science Foundation of China(81872086);the Peking University People's Hospital Scientific Research Developments Funds(RDY2018-18)
目的: 探讨肾透明细胞癌(clear cell renal cell carcinoma，ccRCC)手术后患者中代谢综合征(metabolic syndrome，MetS)与ccRCC预后的相关性。方法: 选择2009年1月—2014年11月于北京大学人民医院行根治性肾切除术或部分肾切除术患者的病例资料进行回顾性分析，共收集到342例ccRCC患者，记录患者的临床资料和病理资料，以及治疗前的实验室检查结果。将患者分为合并MetS组及未合并MetS组，对两组患者的总生存期(overall survival，OS)、肿瘤特异性生存期(cancer-specific survival，CSS)和无进展生存期(progression-free survival，PFS)进行单变量Cox回归分析与亚组分析。对两组患者以及各亚组的OS、CSS以及PFS使用Kaplan-Meier法绘制生存曲线进行生存分析。结果: 单变量Cox回归分析发现，MetS是ccRCC术后OS [风险比(hazard ratio，HR)=0.551，95%CI：0.321~0.949，P=0.031]、CSS(HR=0.460，95%CI 0.234~0.905，P=0.025)以及PFS(HR=0.585，95%CI：0.343~0.998，P=0.049)的保护因素。在肿瘤直径≤4 cm的亚组，MetS与术后OS(HR= 0.857，95%CI：0.389~1.890，P=0.702)、CSS(HR=1.129，95%CI：0.364~3.502，P=0.833)以及PFS(HR=1.554，95%CI：0.625~3.864，P=0.343)无明显相关性。在肿瘤直径>4 cm的亚组，MetS是ccRCC术后OS(HR=0.377，95%CI：0.175~0.812，P=0.013)、CSS(HR=0.280，95%CI：0.113~0.690，P=0.006)以及PFS(HR=0.332，95%CI：0.157~0.659，P=0.002)的保护因素；肥胖是术后CSS(HR=0.464，95%CI：0.219~0.981，P=0.044)和PFS(HR=0.445，95%CI：0.238~0.833，P=0.011)的保护因素。Kaplan-Meier生存分析显示，合并MetS较未合并MetS的患者术后远期生存更佳，二者OS(P=0.029)、CSS(P=0.021)以及PFS(P=0.046)差异均具有统计学意义；对肿瘤直径≤4 cm的亚组，合并MetS与未合并MetS的ccRCC患者术后OS(P=0.702)、CSS(P=0.833)以及PFS(P=0.339)差异均无统计学意义；对肿瘤直径> 4 cm的亚组，合并MetS的患者OS(P=0.010)、CSS(P=0.003)以及PFS(P=0.001)均高于未合并MetS的患者。结论: MetS是ccRCC患者术后OS、CSS和PFS的保护因素，该现象在肿瘤直径>4 cm亚组中更为显著；MetS的组分中肥胖与ccRCC术后OS以及CSS相关。
左美妮 , 杜依青 , 于路平 , 戴翔 , 徐涛 . 代谢综合征与肾透明细胞癌患者预后的相关性[J]. 北京大学学报（医学版）, 2022 , 54(4) : 636 -643 . DOI: 10.19723/j.issn.1671-167X.2022.04.009
Objective: To investigate the effects of MetS on the prognosis of patients with clear cell renal cell carcinoma (ccRCC). Methods: Clinical and pathological data and the laboratory test of ccRCC 342 patients with diverticular stones who underwent ccRCC who underwent radical or partial nephrectomy were retrospectively collected and analyzed.The patients were divided into MetS group and non-MetS group, and the subgroups were defined according to the tumor size. The overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) of the two groups were analyzed by univariate Cox analysis, and the subgroup analyses were also performed. Kaplan-Meier survival curve and survival analysis for OS, CSS, and PFS of the two groups and the subgroups were conducted. Results: Univariate Cox analysis showed that MetS was a protective factor of postoperative OS [hazard ratio (HR)=0.551, 95%CI: 0.321-0.949, P=0.031], CSS (HR=0.460, 95%CI: 0.234-0.905, P=0.025), and PFS (HR 0.585, 95%CI: 0.343-0.998, P=0.049) in the patients with ccRCC. In the subgroup with tumor size≤4 cm, MetS was not associated with postoperative OS (HR=0.857, 95%CI: 0.389-1.890, P=0.702), CSS (HR=1.129, 95%CI: 0.364-3.502, P=0.833), and PFS (HR=1.554, 95%CI: 0.625-3.864, P=0.343). In the subgroup with tumor size>4 cm, Mets was a protective factor of postoperative OS (HR=0.377, 95%CI: 0.175-0.812, P=0.013), CSS (HR=0.280, 95%CI: 0.113-0.690, P=0.006), and PFS (HR=0.332, 95%CI: 0.157-0.659, P=0.002); Obesity was a protective factor of postoperative CSS (HR=0.464, 95%CI: 0.219-0.981, P=0.044), and PFS (HR=0.445, 95%CI: 0.238-0.833, P=0.011). Kaplan-Meier survival analysis showed that the long-term survival of patients with MetS was better than those without MetS in OS (P=0.029), CSS (P=0.021), and PFS (P=0.046); for the subgroup with tumor size≤4 cm, there was no significant difference in postoperative OS (P=0.702), CSS (P=0.833), and PFS (P=0.339) between patients with and without MetS; For the subgroup with tumor size>4 cm, the OS (P=0.010), CSS (P=0.003), and PFS (P=0.001) of patients with MetS were better than those without MetS. Conclusion: MetS was a protective factor of postoperative OS, CSS, and PFS in the patients with ccRCC, which was more obvious in subgroup with tumor size>4 cm. And obesity, the component of MetS, was correlated with postoperative OS and CSS.
| 1 | Bray F , Ferlay J , Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6): 394- 424. |
| 2 | Ozbek E , Otunctemur A , Sahin S , et al. Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome[J]. Asian Pac J Cancer Prev, 2013, 14 (12): 7351- 7354. |
| 3 | Chakiryan NH, Jiang DD, Gillis KA, et al. Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma[J]. JAMA Netw Open, 2021, 4(5): e2111329[2022-03-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150693/. |
| 4 | Jonasch E , Walker CL , Rathmell WK . Clear cell renal cell carcinoma ontogeny and mechanisms of lethality[J]. Nat Rev Nephrol, 2021, 17 (4): 245- 261. |
| 5 | Zhang GM , Zhu Y , Ye DW . Metabolic syndrome and renal cell carcinoma[J]. World J Surg Oncol, 2014, 12, 236. |
| 6 | Yao F , Bo Y , Zhao L , et al. Prevalence and influencing factors of metabolic syndrome among adults in China from 2015 to 2017[J]. Nutrients, 2021, 13 (12): 4475. |
| 7 | Bovolini A , Garcia J , Andrade MA , et al. Metabolic syndrome pathophysiology and predisposing factors[J]. Int J Sports Med, 2021, 42 (3): 199- 214. |
| 8 | Ewertz M , Jensen MB , Gunnarsdóttir K , et al. Effect of obesity on prognosis after early-stage breast cancer[J]. J Clin Oncol, 2011, 29 (1): 25- 31. |
| 9 | Qi J , An R , Bhatti P , et al. Anti-hypertensive medications and risk of colorectal cancer: A systematic review and meta-analysis[J]. Cancer Causes Control, 2022, 33 (6): 801- 812. |
| 10 | Yang X, Li X, Dong Y, et al. Effects of metabolic syndrome and its components on the prognosis of endometrial cancer[J]. Front Endocrinol (Lausanne), 2021, 12: 780769[2022-03-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717682/. |
| 11 | Bulut S , Aktas BK , Erkmen AE , et al. Metabolic syndrome prevalence in renal cell cancer patients[J]. Asian Pac J Cancer Prev, 2014, 15 (18): 7925- 7928. |
| 12 | Yu Y , Gong L , Ye J . The role of aberrant metabolism in cancer: Insights into the interplay between cell metabolic reprogramming, metabolic syndrome, and cancer[J]. Front Oncol, 2020, 10, 942. |
| 13 | Luzzago S , Palumbo C , Rosiello G , et al. Metabolic syndrome predicts worse perioperative outcomes in patients treated with partial nephrectomy for renal cell carcinoma[J]. Urology, 2020, 140, 91- 97. |
| 14 | Zhang Y , Wu T , Xie J , et al. Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma[J]. Int Urol Nephrol, 2021, 53 (10): 2127- 2135. |
| 15 | Kriegmair MC , Mandel P , Porubsky S , et al. Metabolic syndrome negatively impacts the outcome of localized renal cell carcinoma[J]. Horm Cancer, 2017, 8 (2): 127- 134. |
| 16 | Liu Z , Wang H , Zhang L , et al. Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma[J]. Transl Androl Urol, 2019, 8 (5): 507- 518. |
| 17 | Eskelinen TJ , Kotsar A , Tammela TLJ , et al. Components of metabolic syndrome and prognosis of renal cell cancer[J]. Scand J Urol, 2017, 51 (6): 435- 441. |
| 18 | Du Y , Yang W , Liu H , et al. Perirenal fat as a new independent prognostic factor in patients with surgically treated clear cell renal cell carcinoma[J]. Clin Genitourin Cancer, 2022, 20 (1): e75- e80. |
| 19 | Ford E S . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S[J]. Diabetes Care, 2005, 28 (11): 2745- 2749. |
| 20 | Liu M , Wang J , Jiang B , et al. Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001-2010[J]. PLoS One, 2013, 8 (6): e66233. |
| 21 | Capitanio U , Bensalah K , Bex A , et al. Epidemiology of renal cell carcinoma[J]. Eur Urol, 2019, 75 (1): 74- 84. |
| 22 | Miricescu D , Balan DG , Tulin A , et al. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review)[J]. Exp Ther Med, 2021, 21 (5): 540. |
| 23 | Silva A , Pereira SS , Monteiro MP , et al. Effect of metabolic syndrome and individual components on colon cancer characteristics and prognosis[J]. Front Oncol, 2021, 11, 631257. |
| 24 | Mallik R , Chowdhury TA . Metformin in cancer[J]. Diabetes Res Clin Pract, 2018, 143, 409- 419. |
| 25 | Parker AS , Lohse CM , Cheville JC , et al. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma[J]. Urology, 2006, 68 (4): 741- 746. |
| 26 | Wu X , Wang Q , Wang Z , et al. Association of extrarenal invasion patterns and tumor size with the differences in survival outcomes of t3a renal cell carcinoma: a proposal modified T3a stage system is needed[J]. Int J Gen Med, 2022, 15, 367- 378. |
| 27 | Dinatale RG , Xie W , Becerra MF , et al. The association between small primary tumor size and prognosis in metastatic renal cell carcinoma: Insights from two independent cohorts of patients who underwent cytoreductive nephrectomy[J]. Eur Urol Oncol, 2020, 3 (1): 47- 56. |
/
| 〈 |
|
〉 |
